159 related articles for article (PubMed ID: 37882056)
21. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.
Takada K; Sugita S; Murase K; Kikuchi T; Oomori G; Ito R; Hayasaka N; Miyanishi K; Iyama S; Ikeda H; Kobune M; Emori M; Kato J; Hasegawa T
Thorac Cancer; 2019 Dec; 10(12):2312-2315. PubMed ID: 31617320
[TBL] [Abstract][Full Text] [Related]
22. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract][Full Text] [Related]
23. FDG PET/CT in a Case With Cellular Schwannoma of the Kidney.
Yu Z; Zhang J; Dong A; Zhu Y
Clin Nucl Med; 2022 Nov; 47(11):996-997. PubMed ID: 35619199
[TBL] [Abstract][Full Text] [Related]
24. Infrequent loss of SMARCA4, SMARCA2, and SMARCB1 expression in uterine mesenchymal tumors.
Kihara A; Amano Y; Matsubara D; Fukushima N; Fujiwara H; Niki T
Hum Pathol; 2021 Oct; 116():12-21. PubMed ID: 34271067
[TBL] [Abstract][Full Text] [Related]
25. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
26. SMARCA4-deficient thoracic sarcoma: report of a case and insights into how to reach the diagnosis using limited samples and resources.
Kuwamoto S; Matsushita M; Takeda K; Tanaka N; Endo Y; Yamasaki A; Kohashi K; Oda Y; Horie Y
Hum Pathol; 2017 Dec; 70():92-97. PubMed ID: 28601660
[TBL] [Abstract][Full Text] [Related]
27. Role of ¹⁸F-FDG PET/CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients.
Choi HS; Yoo IeR; Park HL; Choi EK; Kim SH; Lee WH
Clin Imaging; 2014; 38(2):109-14. PubMed ID: 24361174
[TBL] [Abstract][Full Text] [Related]
28. Solitary Chest Wall Tuberculosis Mimicking a Malignancy Demonstrated on FDG PET/CT.
Xiao L; Li Y; Li L
Clin Nucl Med; 2022 Sep; 47(9):e609-e610. PubMed ID: 35439192
[TBL] [Abstract][Full Text] [Related]
29.
He Q; Xiao L; Li Y
Hell J Nucl Med; 2023; 26(1):73-74. PubMed ID: 37031425
[TBL] [Abstract][Full Text] [Related]
30. [Thoracic
Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
[TBL] [Abstract][Full Text] [Related]
31. 18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus?
Sharma P; Kumar R; Jeph S; Karunanithi S; Naswa N; Gupta A; Malhotra A
Nucl Med Commun; 2011 Sep; 32(9):782-8. PubMed ID: 21799368
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and management of gastrointestinal SMARCA4-deficient undifferentiated tumors.
Wang J; Elghawy O; Kurpiel B; Kaur V
Clin J Gastroenterol; 2023 Dec; 16(6):807-814. PubMed ID: 37651059
[TBL] [Abstract][Full Text] [Related]
33. Thoracic SMARCA2-deficient But SMARCA4-preserved Tumors With Undifferentiated Morphology Combined With Claudin-4 Negativity.
Iwakoshi A; Sasaki E; Sato M; Sugiyama K; Kogure Y; Kitagawa C; Nishimura R
Am J Surg Pathol; 2022 Jul; 46(7):1000-1006. PubMed ID: 35220352
[TBL] [Abstract][Full Text] [Related]
34. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
35. Primary cutaneous SMARCA4-deficient undifferentiated malignant neoplasm: A rare case report and literature review.
Gumusgoz E; Graham BS; Hosler GA
J Cutan Pathol; 2024 Apr; 51(4):262-266. PubMed ID: 38124373
[TBL] [Abstract][Full Text] [Related]
36. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report.
Iijima Y; Sakakibara R; Ishizuka M; Honda T; Shirai T; Okamoto T; Tateishi T; Sakashita H; Tamaoka M; Takemoto A; Kumaki Y; Ikeda S; Miyazaki Y
Immunotherapy; 2020 Jun; 12(8):563-569. PubMed ID: 32363992
[TBL] [Abstract][Full Text] [Related]
37. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
38. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A; Jain D
Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
[TBL] [Abstract][Full Text] [Related]
39. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
[TBL] [Abstract][Full Text] [Related]
40. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses.
Perret R; Chalabreysse L; Watson S; Serre I; Garcia S; Forest F; Yvorel V; Pissaloux D; Thomas de Montpreville V; Masliah-Planchon J; Lantuejoul S; Brevet M; Blay JY; Coindre JM; Tirode F; Le Loarer F
Am J Surg Pathol; 2019 Apr; 43(4):455-465. PubMed ID: 30451731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
